Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer
Zhaojun Qiu, Deepika Sigh, Yujie Liu, Chandra B Prasad, Nichalos Bean, Chunhong Yan, Zaibo Li, Xiaoli Zhang, Goutham Narla, Analisa DiFeo, Qi-En Wang, Junran Zhang · 2024
Read Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer by Zhaojun Qiu, Deepika Sigh, Yujie Liu, Chandra B Prasad, Nichalos Bean, Chunhong Yan, Zaibo Li, Xiaoli Zhang, Goutham Narla, Analisa DiFeo, Qi-En Wang, Junran Zhang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11626944.txt.
Description
Zhaojun Qiu and co-authors hunted for a marker in ovarian cancer in two thousand twenty-four. The cancer type is the deadliest form of ovarian cancer. Drugs that block a cell checkpoint protein show promise against it. That protein helps cancer cells survive stress as they copy DNA. A second protein complex can tune how well the blocker works.
The team focused on tumors with low levels of one regulator unit. Low levels made cancer cells more sensitive to the blocking drug. That link was known in lung cancer but not in ovarian tumors. A clear marker would help doctors pick patients for trials. It could raise benefit while sparing others needless side effects. The study makes the case for testing the marker in clinic trials.
Catalog record
| CREATOR | Zhaojun Qiu, Deepika Sigh, Yujie Liu, Chandra B Prasad, Nichalos Bean, Chunhong Yan, Zaibo Li, Xiaoli Zhang, Goutham Narla, Analisa DiFeo, Qi-En Wang, Junran Zhang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |